Table 2 Tumor histologies and locations of the biopsies obtained for microarray analysis of the patients in the training set
From: A novel genomic signature predicting FDG uptake in diverse metastatic tumors
Histology | Total (n = 71) | Percentage (%) |
Colorectal cancer | 9.0 | 12.7 |
Breast cancer | 8.0 | 11.3 |
Soft tissue sarcoma | 7.0 | 9.9 |
Genitourinary tumor | 7.0 | 9.9 |
Ovarian cancer | 7.0 | 9.9 |
Lung cancer | 7.0 | 9.9 |
Pancreatic cancer | 6.0 | 8.5 |
Head and neck cancer | 5.0 | 7.0 |
Esophageal cancer | 4.0 | 5.6 |
Thyroid cancer | 2.0 | 2.8 |
Bile duct cancer | 2.0 | 2.8 |
Carcinoma of unknown primary (CUP) | 1.0 | 1.4 |
Gastric cancer | 1.0 | 1.4 |
Lymphoma | 1.0 | 1.4 |
Melanoma | 1.0 | 1.4 |
Mesothelioma | 1.0 | 1.4 |
Merkel cell carcinoma | 1.0 | 1.4 |
Kidney cancer | 1.0 | 1.4 |
Locations of biopsies | Total (n = 71) | Percentage (%) |
Liver | 25 | 35.2 |
Retroperitoneal | 16 | 22.5 |
Lymphadenopathy | 13 | 18.3 |
Head and neck mucosa | 3 | 4.2 |
Skin | 3 | 4.2 |
Pleural | 3 | 4.2 |
Lung | 3 | 4.2 |
Breast | 2 | 2.8 |
Mediastinum | 2 | 2.8 |
Pancreas | 1 | 1.4 |